Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“Treatment after EVP in bladder cancer is undefined. Izalontamab Brenitecan (HER2/3 TROP2 ADC) has good activity in bladder+lung cancer.
A global randomised phase III has started enrolment Iza Bren alone vs platinum chemo in previously treated pts (including EVP).”
More posts featuring Bladder Cancer on OncoDaily.